The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Autor:	Townsend EC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Murakami MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Christodoulou A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Christie AL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Köster J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA; Center for Functional Cancer Epigenomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., DeSouza TA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Morgan EA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA., Kallgren SP; Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA., Liu H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Wu SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Plana O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Montero J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Stevenson KE; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Rao P; Center for Functional Cancer Epigenomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Vadhi R; Center for Functional Cancer Epigenomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Andreeff M; Leukemia Division, MD Anderson Cancer Center, Houston, TX 77030, USA., Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Ballen KK; Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA., Barzaghi-Rinaudo P; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland., Cahill S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Clark RA; Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115, USA., Cooke VG; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., DeAngelo DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Dorfman DM; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA., Eaton H; Office of Research and Technology Ventures, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ebert BL; Department of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA., Etchin J; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Firestone B; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland., Fisher DC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Freedman AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Galinsky IA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Gao H; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland., Garcia JS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Garnache-Ottou F; EFS Bourgogne Franche Comté, INSERM UMR1098, 25020 Besançon, France., Graubert TA; Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA., Gutierrez A; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Halilovic E; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland., Harris MH; Department of Pathology, Boston Children's Hospital, Boston, MA 02215, USA., Herbert ZT; Molecular Biology Core Facility, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Horwitz SM; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA., Inghirami G; Department of Pathology, Weill Cornell Medical College, New York, NY 10065, USA., Intlekofer AM; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA., Ito M; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland., Izraeli S; Functional Genomics and Leukemia Research, Sheba Medical Center, Tel Hashomer and Tel Aviv University, Ramat Gan, 52621, Israel., Jacobsen ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Jacobson CA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Jeay S; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland., Jeremias I; Department of Gene Vectors, Helmholtz Zentrum München, German Research Center for Environmental Health, Marchioninistraße 25, 81377 Munich, Germany; Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig Maximilians University, Lindwurmstraße 4, 80337 Munich, Germany., Kelliher MA; Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01655, USA., Koch R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Konopleva M; Leukemia Division, MD Anderson Cancer Center, Houston, TX 77030, USA., Kopp N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Kornblau SM; Leukemia Division, MD Anderson Cancer Center, Houston, TX 77030, USA., Kung AL; Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA., Kupper TS; Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115, USA., LeBoeuf NR; Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115, USA., LaCasce AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Lees E; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland., Li LS; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Look AT; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Murakami M; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland., Muschen M; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA., Neuberg D; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ng SY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Odejide OO; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Orkin SH; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Paquette RR; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Place AE; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Roderick JE; Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01655, USA., Ryan JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Sallan SE; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Shoji B; Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA., Silverman LB; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Soiffer RJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Steensma DP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Stone RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Tamburini J; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France., Thorner AR; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02215, USA., van Hummelen P; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Wadleigh M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Wiesmann M; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland., Weng AP; Department of Pathology, British Columbia Cancer Research Center, Vancouver V5Z 1H8, Canada., Wuerthner JU; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland., Williams DA; Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA., Wollison BM; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Lane AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Letai A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Bertagnolli MM; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA., Ritz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Brown M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA; Center for Functional Cancer Epigenomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Long H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA; Center for Functional Cancer Epigenomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Aster JC; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA., Shipp MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Griffin JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA., Weinstock DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address: dweinstock@partners.org.
Jazyk:	angličtina
Zdroj:	Cancer cell [Cancer Cell] 2016 Apr 11; Vol. 29 (4), pp. 574-586.
DOI:	10.1016/j.ccell.2016.03.008
Abstrakt:	More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX) in mice could efficiently define therapeutic activity across heterogeneous tumors. To address this hypothesis, we established a large, publicly available repository of well-characterized leukemia and lymphoma PDXs that undergo orthotopic engraftment, called the Public Repository of Xenografts (PRoXe). PRoXe includes all de-identified information relevant to the primary specimens and the PDXs derived from them. Using this repository, we demonstrate that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease. (Copyright © 2016 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu